392 related articles for article (PubMed ID: 11103757)
1. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
3. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
[TBL] [Abstract][Full Text] [Related]
7. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
Kamali F; Edwards C; Butler TJ; Wynne HA
Thromb Haemost; 2000 Jul; 84(1):39-42. PubMed ID: 10928467
[TBL] [Abstract][Full Text] [Related]
8. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
9. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
[TBL] [Abstract][Full Text] [Related]
10. Absence of a pharmacokinetic interaction between etanercept and warfarin.
Zhou H; Patat A; Parks V; Buckwalter M; Metzger D; Korth-Bradley J
J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
[TBL] [Abstract][Full Text] [Related]
11. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black DJ; Kunze KL; Wienkers LC; Gidal BE; Seaton TL; McDonnell ND; Evans JS; Bauwens JE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):422-8. PubMed ID: 8801057
[TBL] [Abstract][Full Text] [Related]
12. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
Margaglione M; Brancaccio V; Ciampa A; Di Minno G
Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
[No Abstract] [Full Text] [Related]
13. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
Burstein AH; Clark DJ; O'Gorman M; Willavize SA; Brayman TG; Grover GS; Walsky RL; Obach RS; Faessel HM
J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
[TBL] [Abstract][Full Text] [Related]
14. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients.
McAleer SD; Foondun AS; Feely M; Chrystyn H
Chirality; 1997; 9(1):13-6. PubMed ID: 9094197
[TBL] [Abstract][Full Text] [Related]
15. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
[TBL] [Abstract][Full Text] [Related]
19. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Oberwittler H; Hirschfeld-Warneken A; Wesch R; Willerich H; Teichert L; Lehr KH; Ding R; Haefeli WE; Mikus G
J Clin Pharmacol; 2007 Jan; 47(1):70-7. PubMed ID: 17192504
[TBL] [Abstract][Full Text] [Related]
20. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
